-
公开(公告)号：US06355245B1
公开(公告)日：2002-03-12
申请号：US08487283
申请日：1995-06-07
申请人： Mark J. Evans , Louis A. Matis , Eileen Elliott Mueller , Steven H. Nye , Scott Rollins , Russell P. Rother , Jeremy P. Springhorn , Stephen P. Squinto , Thomas C. Thomas , James A. Wilkins
发明人： Mark J. Evans , Louis A. Matis , Eileen Elliott Mueller , Steven H. Nye , Scott Rollins , Russell P. Rother , Jeremy P. Springhorn , Stephen P. Squinto , Thomas C. Thomas , James A. Wilkins
IPC分类号： A61K39395
CPC分类号： C07K14/472 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
摘要翻译： 公开了使用抗C5抗体，例如单克隆抗体来治疗肾小球性肾炎（GN）。 已经发现以低剂量水平施用此类抗体显着降低与GN相关的肾小球炎症/扩大和其它病理状况。 还公开了抗C5抗体和抗-C5抗体编码核酸分子。 这些抗体可用于治疗GN和涉及补体系统的病理活化的其它炎性病症。
-
公开(公告)号：US6040428A
公开(公告)日：2000-03-21
申请号：US276197
申请日：1999-03-25
IPC分类号： C07K14/705 , C12N15/12 , C07K14/47
CPC分类号： C07K14/70564
摘要： A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.
摘要翻译： 公开了猪E-选丝蛋白，其氨基酸序列，编码蛋白质的cDNA的序列，与蛋白质反应的抗体，以及使用这些分子的方法。 这些分子用于诊断异种移植的猪器官的排斥，以及预防和治疗这种移植排斥反应。
-
公开(公告)号：US5891645A
公开(公告)日：1999-04-06
申请号：US252493
申请日：1994-06-01
IPC分类号： C07K14/705 , C12N15/12 , C12N15/63 , C12N15/85 , C12P21/02
CPC分类号： C07K14/70564
摘要： A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.
-
4.发明授权Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopes 失效通过降低半乳糖α（1,3）半乳糖基表位的表达或识别来保护逆转录病毒载体颗粒和生产细胞免于由补体失活的方法和组合物
公开(公告)号：US5871997A
公开(公告)日：1999-02-16
申请号：US399416
申请日：1995-03-06
申请人： Russell P. Rother , Scott A. Rollins , William L. Fodor , Jeremy P. Springhorn , Stephen P. Squinto
发明人： Russell P. Rother , Scott A. Rollins , William L. Fodor , Jeremy P. Springhorn , Stephen P. Squinto
IPC分类号： C12N15/09 , A61K35/76 , C07K16/10 , C07K16/18 , C12N5/10 , C12N15/867 , C12N7/00 , C12N5/00 , C12N7/02 , C12N7/06
CPC分类号： C12N15/86 , C07K16/1036 , C07K16/18 , C12N2740/13043 , C12N2740/13051
摘要： Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.
摘要翻译： 提供了方法和组合物，用于促进涉及在含补体的体液存在下用逆转录病毒载体颗粒转导靶细胞的基因治疗方法。 已经发现，在反转录病毒载体颗粒上降低半乳糖α（1,3）半乳糖基表位的水平和/或与这种表位结合的抗体的阻断已经使得颗粒对于通过补体介导的机制失活而较不敏感，并因此允许 在含有体液的补体存在下的转导。 提供了获得这种减少的方法。
-
公开(公告)号：US5562904A
公开(公告)日：1996-10-08
申请号：US278550
申请日：1994-07-21
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P43/00 , C07K16/18 , C12P21/08 , B61K39/395
摘要： Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The administration of soluble complement inhibitor molecules to body fluids prevents the complement mediated inactivation of the retroviral vector particles, and provides a safety mechanism for such gene therapy procedures, as the action of soluble complement inhibitors is transient, and any retroviral vector particles present after the return of uninhibited complement activity will be inactivated. Preferred soluble complement inhibitors for use in the practice of the present invention include complement inhibitory anti-complement component mAbs (including complement inhibitory anti C5 antibodies).
摘要翻译： 提供了方法和组合物，用于促进涉及在含补体的体液存在下用逆转录病毒载体颗粒转导靶细胞的基因治疗方法。 向体液施用可溶性补体抑制剂分子可防止补体介导的逆转录病毒载体颗粒的失活，并为此类基因治疗程序提供安全机制，因为可溶性补体抑制剂的作用是暂时的，并且任何逆转录病毒载体颗粒存在于 不受限制的补体活动的返回将被灭活。 用于实施本发明的优选的可溶性补体抑制剂包括补体抑制性抗补体成分mAb（包括补体抑制性抗C5抗体）。
-
公开(公告)号：US09447176B2
公开(公告)日：2016-09-20
申请号：US13128523
申请日：2009-11-10
CPC分类号： C07K16/18 , A61K9/0019 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/34
摘要： The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
摘要翻译： 本公开尤其涉及包含人补体抑制剂的组合物和组合物在治疗或预防补体相关疾病的方法中的用途。 在一些实施方案中，将抑制剂长期施用于患者。 在一些实施方案中，抑制剂以一定量和频率施用于患者以维持系统性补体抑制并防止突破。 在一些实施方案中，组合物含有结合人补体成分C5蛋白或蛋白质片段如C5a或C5b的抗体或其抗原结合片段。
-
公开(公告)号：US20120225056A1
公开(公告)日：2012-09-06
申请号：US13128523
申请日：2009-11-10
IPC分类号： A61K39/395 , A61K35/407 , A61K35/23 , A61K35/34 , A61K35/42 , A61P13/12 , A61K35/44 , A61K35/28 , A61K35/12 , A61P7/02 , A61P9/14 , A61K35/00 , A61K35/36
CPC分类号： C07K16/18 , A61K9/0019 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/34
摘要： The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
摘要翻译： 本公开尤其涉及包含人补体抑制剂的组合物和组合物在治疗或预防补体相关疾病的方法中的用途。 在一些实施方案中，将抑制剂长期施用于患者。 在一些实施方案中，抑制剂以一定量和频率施用于患者以维持系统性补体抑制并防止突破。 在一些实施方案中，组合物含有结合人补体成分C5蛋白或蛋白质片段如C5a或C5b的抗体或其抗原结合片段。
-
8.发明申请REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS 审中-公开用于检测PNH II型白细胞的试剂和方法及其作为血栓病症风险因子的鉴定公开(公告)号：US20130045192A1
公开(公告)日：2013-02-21
申请号：US13508909
申请日：2010-11-09
IPC分类号： G01N33/566 , A61P7/00 , A61K31/727 , A61P7/02 , A61K35/14 , A61K38/49
CPC分类号： G01N33/5094 , A61K31/352 , A61K31/56 , A61K31/727 , A61K35/19 , A61K38/196 , A61K38/4886 , C07K16/40 , G01N33/56972 , G01N33/6893 , G01N2800/226
摘要： The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
摘要翻译： 本公开涉及用于检测生物样品中PNH II型细胞群的方法，以及用于基于患者血液中PNH II型细胞的百分比来确定患者是否处于发生血小板减少症或血栓形成的风险增加的方法。 本公开还涉及用于该方法的试剂和共轭物。
-
9.发明申请Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement 审中-公开阵发性夜间血红蛋白尿患者由补体抑制剂治疗公开(公告)号：US20090220508A1
公开(公告)日：2009-09-03
申请号：US12225040
申请日：2007-03-15
申请人： Leonard Bell , Russell P. Rother
发明人： Leonard Bell , Russell P. Rother
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/7105 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565
摘要： Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
摘要翻译： 厄洛珠单抗是抑制末端补体激活的C5的人源化单克隆抗体，在阵发性夜间血红蛋白尿（PNH）患者的小队列中，在初步的12周开放标签试验中显示出活性。 本研究检查了在双盲，随机，安慰剂对照，多中心全球III期试验中，慢性eculizumab治疗是否可以减少血管内溶血，稳定血红蛋白水平，降低输血需求，提高生活质量。 已经发现，通过减少血管内溶血，厄库珠单抗稳定了血红蛋白水平，降低了输血的需要，并改善PNH患者的生活质量。 慢性eculizumab治疗似乎是PNH的安全有效的治疗方法。
-
10.发明申请ANTIBODIES TO OX-2/CD200 AND USES THEREOF IN INHIBITING IMMUNE RESPONSES 有权OX-2 / CD200的抗体及其在抑制免疫应答中的用途公开(公告)号：US20120321625A1
公开(公告)日：2012-12-20
申请号：US13533546
申请日：2012-06-26
IPC分类号： A61K39/395 , A61K38/13 , A61K31/395 , A61P37/06
CPC分类号： C07K16/2803 , A61K39/39541 , A61K2039/505 , C07K2317/52 , A61K2300/00
摘要： This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
摘要翻译： 本公开提供了用于抑制免疫应答的方法和组合物。 本公开还提供了用于抑制移植物排斥和促进或延长移植物存活的方法和组合物。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.049 秒)